Stock comparison
JOHNSON & JOHNSON is 72.6x more valuable than Spyre Therapeutics, Inc. by market capitalization ($622.64 B vs $8.58 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 72.6x more valuable than Spyre Therapeutics, Inc. by market capitalization ($622.64 B vs $8.58 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 72.6x more valuable than Spyre Therapeutics, Inc. by market capitalization ($622.64 B vs $8.58 B).
Revenue leader
JNJ
SYRE: $0.00 vs JNJ: $94.19B.
Profit leader
JNJ
SYRE: -$155.20M vs JNJ: $26.80B.
| Metric | SYRE | JNJ |
|---|---|---|
| Market cap | $8.58 B | $622.64 B |
| US-listed rank | #1053 | #18 |
| Revenue (latest FY) | $0.00 | $94.19B |
| Net income (latest FY) | -$155.20M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 23.2x |
| SEC filings | 762 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 72.6x more valuable than Spyre Therapeutics, Inc. by market capitalization ($622.64 B vs $8.58 B).
In their latest fiscal years, Spyre Therapeutics, Inc. reported $0.00 in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Spyre Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.